Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study - The Lancet Gastroenterology & Hepatology
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Main clinical trials with gemcitabine and nab-paclitaxel in other... | Download Table
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer | British Journal of Cancer
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
ABRAXANE® for Metastatic Pancreatic Cancer | for HCPs
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐ paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis - Schlick - 2023 - Cancer Medicine - Wiley Online Library
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
Nab-paclitaxel (Abraxane®) - Pancreatic Cancer UK
Choice for Metastatic Pancreatic Cancer: FOLFIRINOX or Gemcitabine/Nab- Paclitaxel? - The ASCO Post
GI Chemotherapy Education – GA/GemNab: Gemcitabine and Nab-paclitaxel (Abraxane®) - YouTube
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer | Scientific Reports
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
Cancers | Free Full-Text | Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
Gemcitabine-Nab-Paclitaxel Regimen PHARMACY
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives - ScienceDirect
Cancers | Free Full-Text | Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
